680 related articles for article (PubMed ID: 16076937)
1. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
2. In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties.
Mathews JL; Fulton BS; Negus SS; Neumeyer JL; Bidlack JM
Neurochem Res; 2008 Oct; 33(10):2142-50. PubMed ID: 18528756
[TBL] [Abstract][Full Text] [Related]
3. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
Neumeyer JL; Zhang A; Xiong W; Gu XH; Hilbert JE; Knapp BI; Negus SS; Mello NK; Bidlack JM
J Med Chem; 2003 Nov; 46(24):5162-70. PubMed ID: 14613319
[TBL] [Abstract][Full Text] [Related]
6. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
7. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
8. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
9. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.
Greiner E; Spetea M; Krassnig R; Schüllner F; Aceto M; Harris LS; Traynor JR; Woods JH; Coop A; Schmidhammer H
J Med Chem; 2003 Apr; 46(9):1758-63. PubMed ID: 12699394
[TBL] [Abstract][Full Text] [Related]
12. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
13. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
[TBL] [Abstract][Full Text] [Related]
14. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.
Khotib J; Narita M; Suzuki M; Yajima Y; Suzuki T
Neuropharmacology; 2004 Mar; 46(4):531-40. PubMed ID: 14975677
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
Lester PA; Traynor JR
Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
[TBL] [Abstract][Full Text] [Related]
17. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
[TBL] [Abstract][Full Text] [Related]
18. (2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.
Hosohata K; Varga EV; Alfaro-Lopez J; Tang X; Vanderah TW; Porreca F; Hruby VJ; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 2003 Feb; 304(2):683-8. PubMed ID: 12538822
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.
Spetea M; Schüllner F; Moisa RC; Berzetei-Gurske IP; Schraml B; Dörfler C; Aceto MD; Harris LS; Coop A; Schmidhammer H
J Med Chem; 2004 Jun; 47(12):3242-7. PubMed ID: 15163203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
